Agulla H L, Pollock R R, Spira G, Scharff M D
Albert Einstein College of Medicine, Bronx, New York 10461, USA.
The Faculty of Medicine and The Rappaport Family Institute for The Medical Sciences, Technicon, Haifa, Israel.
Immunol Today. 1986 Dec;7(12):380-3. doi: 10.1016/0167-5699(86)90031-9.
In last month's issue(1) Matthew Scharff and his colleagues discussed recent improvements in the technique of making monoclonal antibodies by cell fusion. However, not all the monoclonal antibodies generated by hybridoma technology have all of the properties required for a particular task. This second part of a two-part review deals with ways in which these first-generation reagents can be improved by identifying somatic-cell mutants with the desired properties or by engineering new and even novel molecules using recombinant DNA technology.
在上一期杂志（1）中，马修·沙夫及其同事讨论了通过细胞融合制备单克隆抗体技术的最新进展。然而，并非通过杂交瘤技术产生的所有单克隆抗体都具备特定任务所需的全部特性。这篇分为两部分的综述的第二部分讨论了通过鉴定具有所需特性的体细胞突变体或利用重组DNA技术构建新的甚至全新的分子来改进这些第一代试剂的方法。
